Chinook Therapeutics Inc (KDNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -16,094 | -11,410 | -7,784 | -16,050 |
| Depreciation Amortization | 162 | 94 | 43 | 120 |
| Accounts receivable | 233 | 244 | 337 | N/A |
| Accounts payable and accrued liabilities | 598 | 2,633 | 219 | N/A |
| Other Working Capital | 11,673 | 16,298 | 958 | -240 |
| Other Operating Activity | -2,328 | -3,898 | 1,253 | 1,940 |
| Operating Cash Flow | $-5,756 | $3,961 | $-4,974 | $-14,230 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -478 | -267 | -126 | -170 |
| Investing Cash Flow | $-478 | $-267 | $-126 | $-170 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | 308 | 308 | 308 | N/A |
| Common Stock Issued | 49 | 0 | N/A | N/A |
| Other Financing Activity | 36,896 | 26,905 | 0 | 19,230 |
| Financing Cash Flow | $37,253 | $27,213 | $308 | $19,230 |
| Beginning Cash Position | 8,532 | 8,532 | 8,532 | 3,690 |
| End Cash Position | 39,551 | 39,439 | 3,740 | 8,530 |
| Net Cash Flow | $31,019 | $30,907 | $-4,792 | $4,830 |
| Free Cash Flow | ||||
| Operating Cash Flow | -5,756 | 3,961 | -4,974 | -14,230 |
| Capital Expenditure | -478 | -267 | -126 | N/A |
| Free Cash Flow | -6,234 | 3,694 | -5,100 | -14,230 |